Boehringer Ingelheim
  • Therapeutic Area
    • Metabolic
      CV Risk in T2DEMPRISE StudyEMPA-REG Outcome TrialThrive SummitEMPA-KIDNEY Trial
    • Cardiovascular
      Reversibility Mode of ActionIndication
    • Respiratory
  • Products
    All products
    • Metabolic
      JardianceSynjardy
    • Cardiovascular
      PradaxaActilyseMetalysePritor
    • Respiratory
      Spiriva
  • Resources
  • Contact
za
Login

 

Clinical Studies

VIDEOS

Clinical studies

WISDOM Trial

icoPDF

WISDOM Trial
UPLIFT Clinical Trial Summary

icoPDF

UPLIFT Clinical Trial Summary
COPD Treatment: GOLD Guidelines Infographic

icoPDF

COPD Treatment: GOLD Guidelines Infographic
Spiriva Exacerbation Data vs Anoro

icoPDF

Spiriva Exacerbation Data vs Anoro
Spiriva vs Salmeterol: Time to first excacerbation

icoPDF

Spiriva vs Salmeterol: Time to first excacerbation
 Spiriva vs Salmeterol: Severe Excacerbation data

icoPDF

Spiriva vs Salmeterol: Severe Excacerbation data
COPD Symptom Checker

icoPDF

COPD Symptom Checker
Surgical Intervention

Surgical Intervention
Indication and Dosage

icoPDF

Indication and Dosage
Risk vs Benefit

icoPDF

Risk vs Benefit
Precautions When Using Actilyse

icoPDF

Precautions When Using Actilyse
Minimising the Risk of Bleeding

icoPDF

Minimising the Risk of Bleeding
Monitoring for Major and Minor Bleeding

icoPDF

Monitoring for Major and Minor Bleeding
Risk Factors for ICH

icoPDF

Risk Factors for ICH
Bleed Management Overview

icoPDF

Bleed Management Overview
AHA/ASA Recommendations for Managing sICH

icoPDF

AHA/ASA Recommendations for Managing sICH
AHA/ASA: Reversal Agents

icoPDF

AHA/ASA: Reversal Agents
Contra-indications

icoPDF

Contra-indications
Telmisartan unique attributes

icoPDF

Telmisartan unique attributes
24 Hour BP Control

icoPDF

24 Hour BP Control
Cardio metabolic patients

icoPDF

Cardio Metabolic Patients
ONTARGET trial

icoPDF

ONTARGET trial
Telmisartan unique attributes

icoPDF

Telmisartan unique attributes
24 Hour BP Control

icoPDF

24 Hour BP Control
Cardio metabolic patients

icoPDF

Cardio Metabolic Patients
Guidelines for the management of Acute Ischaemic Stroke

icoPDF

Guidelines for the management of Acute Ischaemic Stroke
Endovascular Therapy

icoPDF

Endovascular Therapy
Actilyse Stroke - Act FAST

icoPDF

Actilyse Stroke - Act FAST
The increasing burden of stroke

icoPDF

The increasing burden of stroke
The importance of treating stroke as an emergency

icoPDF

The importance of treating stroke as an emergency
Early treatment of stroke is great benefit to your patient

icoPDF

Early treatment of stroke is great benefit to your patient
Clinical presentation, diagnosis, and management of pulmonary embolism

icoPDF

Clinical presentation, diagnosis, and management of pulmonary embolism
Atrial fibrillation and stroke

icoPDF

Atrial fibrillation and stroke
An overview of Atrial Fibrillation (AF)

icoPDF

An overview of Atrial Fibrillation (AF)
Stroke prevention in Atrial Fibrillation (AF)

icoPDF

Stroke prevention in Atrial Fibrillation (AF)
Mechanisms of anticoagulation

icoPDF

Mechanisms of anticoagulation
Managament of deep vein thrombosis

icoPDF

Managament of deep vein thrombosis
INPULSIS-ON
Efficacy
Reimbursement Information
Reimbursement Information
Dosage
Dosage
INPULSIS-ON
Mechanism of Action
Pradaxa:Mechanism of Action
Pradaxa:Mechanism of Action
RE-DUAL PCI

icoPDF

RE-DUAL PCI
Safety & Tolerability
Safety & Tolerability
Load more

BI LEARNING

Ethics: Distributive Justice
Ethics: Distributive Justice
Ethics: Professionalism Ethics
Ethics: Professionalism Ethics
Hypertension 1
Hypertension 1
Hypertension 2
Hypertension 2
Load more
  • Therapeutic Area
  • Metabolic
  • Cardiovascular
  • Respiratory
  • Resources
  • Videos
  • Clinical Studies
  • BI Learning
  • Site map
  • Privacy
  • Terms of use
  • Contact
  • Change country

© 2010-2021
Boehringer Ingelheim International GmbH.
All rights reserved.